Please assess the completion status of the following clinical trial:

Trial Title: 12-week Study to Evaluate RebiSmart™ Suitability for Self Injection in Relapsing Multiple Sclerosis.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females between 18 and 65 years of age, inclusive~* Female subjects must be neither pregnant nor breast-feeding and must lack child-bearing potential, as defined by either:~  * Post-menopausal or surgically sterile, or~ * Using a highly effective method of contraception for the duration of the study. This is defined as a method that result in a low failure rate (i.e., less than 1% per year) when used consistently and correctly, and includes for instance implants, injectables, combined oral contraceptives, intra-uterine device (IUD)s, sexual abstinence or vasectomised partner.~* Have RMS according to the revised McDonald Criteria 2005~* Have disease duration for at least 3 months~* Are currently receiving RNF 44 mcg sc by Rebiject IITM (RII) tiw and have been consistently on therapy for a minimum of 6 weeks prior to Screening~Exclusion Criteria:~* Have any disease other than MS that could better explain his/her signs and symptoms~* Receive any other injectable medications on a regular basis during the week prior to the screening period or throughout the duration of the study. The administration of a single injection for treatment or prophylaxis of a condition unrelated to the patient's MS or the patient's RNF therapy (e.g., influenza or pneumococcus vaccination) will be acceptable~* Receive any MS therapy other than Rebif / RNF (e.g., other disease-modifying drug \[DMD\]s: immunomodulatory , immunosuppressive agents or combination therapy) within 12 months prior to study enrolment or at any time during the study~* Receive oral or systemic corticosteroids or adrenocorticotrophic hormone (ACTH) within 30 days prior to SD1~* Have inadequate liver function, defined by a alanine aminotransferase (ALT) \> 3 x upper limit of normal (ULN), or alkaline phosphatase \> 2 x ULN, or total bilirubin \> 2 x ULN if associated with any elevation of ALT or alkaline phosphatase~* Have inadequate bone marrow reserve, defined as a white blood cell count less than 0.5 x lower limit of normal~* Have moderate to severe renal impairment~* History of any chronic pain syndrome~* Any visual or physical impairment that precludes the subject self-injecting the treatment using the RebiSmartä

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).